SCHEMBL303102

SCHEMBL303102

CCCCC#CCCCCC

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN7 P35236 5/20 0.54
HMGCR P04035 3/20 0.54
RECQL P46063 2/20 0.50
TDP1 Q9NUW8 2/20 0.50
KDM4E B2RXH2 1/20 0.50
MEN1 O00255 1/20 0.50
USP2 O75604 1/20 0.50
ALDH1A1 P00352 1/20 0.50
POLB P06746 1/20 0.50
MAPT P10636 1/20 0.50
HPGD P15428 1/20 0.50
ALOX12 P18054 1/20 0.50
BLM P54132 1/20 0.50
KMT2A Q03164 1/20 0.50
MCL1 Q07820 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
TSHR P16473 3/20 0.47
THRB P10828 1/20 0.47
EPHX2 P34913 2/20 0.42
RAB9A P51151 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9210005 0.97 PTPN7 (0.58) PTPN7HMGCRRECQLTDP1KDM4E
SCHEMBL9210913 0.97 PTPN7 (0.58) PTPN7HMGCRRECQLTDP1KDM4E
SCHEMBL11061073 0.97 PTPN7 (0.58) PTPN7HMGCRRECQLTDP1KDM4E
SCHEMBL9213049 0.97 PTPN7 (0.58) PTPN7HMGCRRECQLTDP1KDM4E
SCHEMBL6461207 0.97 PTPN7 (0.58) PTPN7HMGCRRECQLTDP1KDM4E
SCHEMBL9943932 0.97 PTPN7 (0.58) PTPN7HMGCRRECQLTDP1KDM4E
SCHEMBL9212957 0.97 PTPN7 (0.58) PTPN7HMGCRRECQLTDP1KDM4E
SCHEMBL1760799 0.96 PTPN7 (0.56) PTPN7HMGCRRECQLTDP1KDM4E
SCHEMBL23040316 0.93 PTPN7 (0.61) PTPN7HMGCRRECQLTDP1KDM4E
SCHEMBL9211891 0.93 PTPN7 (0.61) PTPN7HMGCRRECQLTDP1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 179 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260130860-A1 LIPIDS FOR DELIVERY OF THERAPEUTIC AGENTS FLAGSHIP LABS 114, INC. (US) 2026-05-14 US claimed
EP-4687854-A2 LIPIDS AND LIPID-LIKE COMPOUNDS FOR THERAPEUTIC LIPID NANOPARTICLE (LNP) DELIVERY Flagship Labs 114, Inc. (US) 2026-02-11 EP claimed
WO-2024211865-A2 LIPIDS AND LIPID-LIKE COMPOUNDS FOR THERAPEUTIC LIPID NANOPARTICLE (LNP) DELIVERY OMEGA THERAPEUTICS, INC. (US) 2024-10-10 WO claimed
WO-2024073678-A2 PHOSPHOLIPIDS CONTAINING A HETEROCYCLE RING HAVING A TERTIARY AMINE OR AMIDE OMEGA THERAPEUTICS, INC. (US) 2024-04-04 WO claimed
WO-2023225621-A2 LIPIDS FOR DELIVERY OF THERAPEUTIC AGENTS OMEGA THERAPEUTICS, INC. (US) 2023-11-23 WO claimed
EP-2816053-B1 BASE-PROTECTED OLIGONUCLEOTIDE AJINOMOTO KK (JP) 2021-03-24 EP claimed
US-9568821-B2 Patterning process SAMSUNG ELECTRONICS CO., LTD. (KR) 2017-02-14 US claimed
US-9507262-B2 Resist top-coat composition and patterning process SHIN-ETSU CHEMICAL CO., LTD. (JP) 2016-11-29 US claimed
US-20150234278-A1 PATTERNING PROCESS SHIN-ETSU CHEMICAL CO., LTD. (JP) 2015-08-20 US claimed
US-20150234274-A1 RESIST TOP-COAT COMPOSITION AND PATTERNING PROCESS SHIN-ETSU CHEMICAL CO., LTD. (JP) 2015-08-20 US claimed
EP-2181763-B1 Catalyst and process for alkoxylation SHELL INT RESEARCH (NL) 2012-06-20 EP claimed
US-20260130860-A1 LIPIDS FOR DELIVERY OF THERAPEUTIC AGENTS FLAGSHIP LABS 114, INC. (US) 2026-05-14 US disclosed
US-12590219-B2 Phenol compound, conductive paste composition, method for producing conductive paste composition, conductive wire, and method for producing conductive wire SHIN-ETSU CHEMICAL CO., LTD. (JP) 2026-03-31 US disclosed
EP-4687854-A2 LIPIDS AND LIPID-LIKE COMPOUNDS FOR THERAPEUTIC LIPID NANOPARTICLE (LNP) DELIVERY Flagship Labs 114, Inc. (US) 2026-02-11 EP disclosed
EP-4654222-A1 DEEP EUTECTIC LIQUID, BIO-ELECTRODE COMPOSITION, BIO-ELECTRODE, AND METHOD FOR PRODUCING BIO-ELECTRODE SHIN-ETSU CHEMICAL CO., LTD. (JP) 2025-11-26 EP disclosed
US-20060116535-A1 Method of deuteration WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) 2006-06-01 US disclosed
US-20060025596-A1 Method for deuteration or tritiation of heterocyclic ring FUJIFILM WAKO PURE CHEMICAL CORPORATION (JP) 2006-02-02 US disclosed
EP-1577280-A1 METHOD OF DEUTERIZATION Wako Pure Chemical Industries, Ltd. (JP) 2005-09-21 EP disclosed
EP-1561741-A1 METHOD FOR DEUTERATION OR TRITIATION OF HETEROCYCLIC RING Wako Pure Chemical Industries, Ltd. (JP) 2005-08-10 EP disclosed
EP-1535889-A1 METHOD OF DEUTERATING AROMATIC RING Wako Pure Chemical Industries, Ltd. (JP) 2005-06-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060025596-A1 Method for deuteration or tritiation of heterocyclic ring HRH2, HRH4, HDHD5 PTPN7 4294/4885HMGCR 827/4885RECQL 165/4885
US-20260130860-A1 LIPIDS FOR DELIVERY OF THERAPEUTIC AGENTS NSUN3, NSUN2, LDLR PTPN7 2194/4885HMGCR 460/4885RECQL 976/4885
US-20060116535-A1 Method of deuteration ARL1, IDH2, IDH3A PTPN7 3793/4885HMGCR 2654/4885RECQL 431/4885
US-12590219-B2 Phenol compound, conductive paste composition, method for producing conductive paste composition, conductive wire, and method for producing conductive wire PYCARD, NPR1, TNNC1 PTPN7 2430/4885HMGCR 4671/4885RECQL 3520/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.